Although these findings support the role of the IL-2 – IL-2R pathway in MS, the increased levels of the respective parameters more likely represent immune activation during disease progression instead of an intrinsic default mechanism causal to the development of MS. This evidence concerns the gene IL2 and myeloid sarcoma.